Title: Improved survival with MEK inhibition in BRAF-mutated melanoma
Authors: Flaherty, Keith T ×
Robert, Caroline
Hersey, Peter
Nathan, Paul
Garbe, Claus
Milhem, Mohammed
Demidov, Lev V
Hassel, Jessica C
Rutkowski, Piotr
Mohr, Peter
Dummer, Reinhard
Trefzer, Uwe
Larkin, James M G
Utikal, Jochen
Dreno, Brigitte
Nyakas, Marta
Middleton, Mark R
Becker, Jürgen C
Casey, Michelle
Sherman, Laurie J
Wu, Frank S
Ouellet, Daniele
Martin, Anne-Marie
Patel, Kiran
Schadendorf, Dirk
METRIC Study Group
Contributors: Sch√∂ffski, Patrick
Issue Date: Jul-2012
Series Title: New England Journal of Medicine vol:367 issue:2 pages:107-114
Abstract: Activating mutations in serine-threonine protein kinase B-RAF (BRAF) are found in 50% of patients with advanced melanoma. Selective BRAF-inhibitor therapy improves survival, as compared with chemotherapy, but responses are often short-lived. In previous trials, MEK inhibition appeared to be promising in this population.
ISSN: 0028-4793
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Laboratory of Experimental Oncology
× corresponding author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science